Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report.
Autoimmune inner ear disease is a treatable cause of sensorineural hearing loss and it is important for physicians and hearing health professionals to recognize that early diagnosis and proper management strategies may result in stabilization and improvement in hearing. The pathogenesis of autoimmune sensorineural hearing loss remains unclear but antibodies directed against the inner ear and/or cellular effectors have been proposed. Therefore, immunosuppressive drugs such as steroids and methotrexate are administered to interfere with the progression of hearing loss and in some cases have been found to improve hearing. We report herein the history of a patient who was treated by systemic administration of anti-tumor necrosis factor-alpha antibodies for Crohn's disease and who also had associated sensorineural hearing loss. Audiometric follow-up revealed not only the efficacy of tumor necrosis factor-alpha blockade in arresting the hearing loss but also an improvement in hearing of 15 dB on average across all frequencies. Hearing remained stable afterwards.
Staecker
H
H
Division of Otolaryngology, University of Maryland, Baltimore, Maryland, USA.
Lefebvre
P P
PP
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D020274:Autoimmune Diseases of the Nervous System / Q000150:complications / Q000188:drug therapy*; D003424:Crohn Disease / Q000150:complications / Q000188:drug therapy; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha